S SOPHIA GENETICS SA
| Market Cap | $361.21M |
| P/E Ratio | — |
| Forward P/E | -9.00 |
| Dividend Yield | — |
| Beta | 1.04 |
| 52W Range | $2.66 - $5.52 |
| # Hedge Funds | 2 |
| Sector | Healthcare |
| Industry | Health Information Services |
Hedge Fund Ownership
| Investor 2 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Chuck Akre Akre Capital Management | 0.19% | $17.37M | 3,719,140 | — |
| Polen Capital Management Polen Capital Management | 0.00% | $101.00K | 21,738 | Buy |
Insider Trading
| Insider Name of the company insider who made the trade 9 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Kevin PuylaertChief Sales Officer | Sale | 3 | $4.71 | $14.13 | 31 Mar 2026 | 01 Apr 2026 |
| Puylaert KevinChief Sales Officer | Sale | 33 | $4.76 | $157.08 | 19 Mar 2026 | 19 Mar 2026 |
| Menu PhilippeChief Medical Officer | Sale | 608 | $4.79 | $2.91K | 19 Mar 2026 | 19 Mar 2026 |
| Van Well DaanChief Legal Officer | Sale | 684 | $4.79 | $3.27K | 19 Mar 2026 | 19 Mar 2026 |
| Camblong JurgiChief Executive Officer | Sale | 4,486 | $4.77 | $21.41K | 19 Mar 2026 | 19 Mar 2026 |
| Xu ZhenyuChief Scientific Officer | Sale | 608 | $4.78 | $2.91K | 19 Mar 2026 | 19 Mar 2026 |
| CARDOZA GEORGEChief Financial Officer | Sale | 774 | $4.79 | $3.70K | 19 Mar 2026 | 19 Mar 2026 |
| Valente ManuelaChief People Officer | Sale | 380 | $4.79 | $1.82K | 19 Mar 2026 | 19 Mar 2026 |
| Muken RossPresident | Sale | 1,183 | $4.79 | $5.67K | 19 Mar 2026 | 19 Mar 2026 |
Frequently Asked Questions
What is SOPH stock price today?
SOPHIA GENETICS SA (SOPH) is currently trading at $5.04. The stock has a 52-week range of $2.66 to $5.52 and a market capitalization of $361.21M.
Is SOPH a good stock to buy in 2026?
SOPHIA GENETICS SA has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +68.0%. 2 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling SOPH stock?
There have been 9 insider transactions for SOPH in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has SOPH stock performed over the past year?
SOPHIA GENETICS SA (SOPH) has returned +68.0% over the past 12 months. The stock traded between $2.66 and $5.52 during this period, and is currently at $5.04.
Which hedge funds own SOPH (SOPHIA GENETICS SA)?
2 tracked hedge funds currently hold SOPH in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is SOPH's market cap and valuation?
SOPHIA GENETICS SA (SOPH) has a market capitalization of $361.21M. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is SOPH's revenue and profitability?
SOPHIA GENETICS SA reported revenue of $77.27M with net income of N/A and a profit margin of N/A. The stock has a beta of 1.04.
What sector is SOPH in and who are its biggest institutional holders?
SOPHIA GENETICS SA (SOPH) operates in the Healthcare sector. It is held by 2 tracked hedge funds. See the ownership table above for the complete list.